José López-Aguilera

Sep 20, 2023 | mdpi.com | Jorge Perea-Armijo |José López-Aguilera |Rafael González-Manzanares |Cristina Pericet-Rodriguez

1. IntroductionHeart failure (HF) is a syndrome whose prevalence has been increasing in recent decades due to an increase in diagnoses and improved survival due to new therapeutic strategies [1]. Patients with heart failure with reduced ejection fraction (HFrEF) in the chronic phase are in a phase of apparent clinical stability, and despite pharmacological advances that have improved prognoses, these patients have a significant residual risk of clinical deterioration and mortality [1,2].